Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

The Trump administration says it is pulling half a billion dollars from U.S. government-funded research projects to create ...

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

GSK said the upfront settlement amount will be recorded as other operating income in its financial results as an adjusting item in the income statement in the third quarter of 2025. The 2025 and ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Estimated Vaccine Effectiveness ...